The proposed $39bn acquisition of Alexion by AstraZeneca has a particular interest for its chief financial officer Marc Dunoyer who recently spoke to Scrip about his extensive experience in the rare disease space.
When AstraZeneca PLC was weighing up an offer to acquire Alexion Pharmaceuticals Inc., it certainly helped that its chief financial officer Marc Dunoyer was also an expert in rare diseases.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
